Canaccord Genuity Maintains Buy on AbbVie, Raises Price Target to $282

Benzinga · 1d ago
Canaccord Genuity analyst Gary Nachman maintains AbbVie (NYSE:ABBV) with a Buy and raises the price target from $273 to $282.